ArticleFuture oncology (London, England)2024

Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer.

David M O'Malley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.